Apr 09, 2018
Morphotek Announces Agreement to License its Proprietary Eribulin-Linker Payload to Bliss Biopharmaceutical Co., Ltd. for Development of a Therapeutic Antibody-Drug Conjugate (ADC)*
Jan 24, 2018
Morphotek To Present Poster On CA125 Suppression Of Humoral Immune Responses Of Antibodies At The Upcoming ASCO-SITC Clinical Immuno-oncology Symposium
Jan 10, 2018
Morphotek Announces FDA Acceptance Of Investigational New Drug Application For Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202
Dec 11, 2017
Morphotek And Rockefeller University Form A Sponsored Research Agreement To Study The Immunosuppressive Effects Of The Tumor Shed Antigen CA125 And Its Potential Impact In Future Patient Therapies
Dec 07, 2017
Morphotek To Present Its Proprietary RESPECT(TM) Antibody-Drug Conjugate (ADC) Technology At The Upcoming Antibody Engineering & Therapeutics Conference In San Diego
Dec 07, 2017
Morphotek To Present Its Proprietary RESPECT(TM) Antibody-Drug Conjugate (ADC) Technology At The Upcoming Antibody Engineering & Therapeutics Conference In San Diego
Dec 04, 2017
Morphotek Announces Initiation Of Phase 1 Study Of Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202 In Solid Tumors With Folate Receptor Alpha Expression
Nov 13, 2017
Morphotek To Present Its Proprietary RESPECT(TM) Antibody Drug Conjugate (ADC) Technology At The Upcoming 9th Annual PEGS Europe In Lisbon
Sep 19, 2017
Morphotek To Present Preclinical Data On Antibody-Drug Conjugate MORAb-202 At The Upcoming 8th Annual World ADC In San Diego
Sep 06, 2017
Morphotek Announces Collaboration Agreement With The Johns Hopkins University To Research And Develop Novel Monoclonal Antibody-Based Therapies Targeting Missplicing-Associated Surface Antigens
Sep 05, 2017
Morphotek®, Inc. Announces an Agreement with Fujirebio Diagnostics, Inc. to Commercialize the CA125 II Assay as a Companion Diagnostic for Farletuzumab®
Jul 11, 2017
Morphotek Announces Publication Uncovering One Of The Mechanisms By Which The Tumor-Produced CA125 Protein Suppresses Immune-Mediated Killing Via Farletuzumab